Evidence map›Paper›PMID 31691601›Full record

ArticleDrug delivery2019

Dual functional matrix metalloproteinase-responsive curcumin-loaded nanoparticles for tumor-targeted treatment.

Fangyuan Guo, Qiafan Fu, Chenhao Jin, Xugang Ji, Qinying Yan, Qingliang Yang, Danjun Wu, Ying Gao, Weiyong Hong, Aiqin Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Curcumin Administration Routes in Breast Cancer Treatment.International journal of molecular sciences · 2024
    Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Fangyuan GuoCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Qiafan FuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Chenhao JinCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Xugang JiCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Qinying YanCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Qingliang YangCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Danjun WuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Ying GaoCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Weiyong HongCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Aiqin LiZhejiang Share Bio-pharm Co. Ltd, Hangzhou, China.
Gensheng YangCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Zhejiang University of Technology · CNTaizhou Municipal Hospital · CNZhejiang Medicine (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The limitations of anticancer drugs, including poor tumor targeting and weak uptake efficiency, are important factors affecting tumor therapy. According to characteristics of the tumor microenvironment, in this study, we aimed to synthesize matrix metalloproteinase (MMP)-responsive curcumin (Cur)-loaded nanoparticles (Cur-P-NPs) based on amphiphilic block copolymer (MePEG-peptide-PET-PCL) with MMP-cleavable peptide (GPLGIAGQ) and penetrating peptide (r9), modified to improve tumor targeting and cellular uptake. The average size of Cur-P-NPs was 176.9 nm, with a zeta potential of 8.1 mV, and they showed drug entrapment efficiency and a loading capacity of 87.07% ± 0.63% and 7.44% ± 0.16%, respectively. Furthermore, Cur release from Cur-P-NPs was sustained for 144 h at pH 7.4, and the release rate was accelerated under enzyme reaction condition. The MTT assay demonstrated that free P-NPs had favorable biosafety, and the anti-proliferative activity of Cur-P-NPs was positively correlated with Cur concentration in MCF-7 cells. Additionally, the results of cellular uptake, in vivo pharmacokinetics, and biodistribution showed that Cur-P-NPs had a good effect on cellular uptake and tumor targeting, resulting in the best bioavailability in tumor therapy. Therefore, Cur-P-NPs, as a promising drug delivery system, might lead to a new and efficient route for targeted therapy in clinical practice.

Indexed as

AnimalsAntineoplastic AgentsBiological AvailabilityCell Line, TumorCurcuminDrug CarriersDrug Delivery SystemsFemaleHumansMatrix MetalloproteinasesMCF-7 CellsMice, NudeNanoparticlesNeoplasmsParticle SizePolyestersAntineoplastic AgentsCurcuminDrug CarriersMatrix Metalloproteinasesmethoxy poly(ethylene glycol-co-epsilon-caprolactone)PolyestersPolyethylene GlycolsPolymersCell-penetrating peptidecleavable peptidecurcuminenzyme-responsive nanoparticletargeting drug delivery

Identifiers

PMID31691601
PMCPMC6844435
OpenAlexW2984458573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.